Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-preserved

195Citations
Citations of this article
133Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims: Heart failure is characterized by recurrent hospitalizations, but often only the frst event is considered in clinical trial reports. In chronic diseases, such as heart failure, analysing all events gives a more complete picture of treatment beneft. We describe methods of analysing repeat hospitalizations, and illustrate their value in one major trial. Methods: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study and results: compared candesartan with placebo in 3023 patients with heart failure and preserved systolic function. The heart failure hospitalization rates were 12.5 and 8.9 per 100 patient-years in the placebo and candesartan groups, respectively. The repeat hospitalizations were analysed using the Andersen-Gill, Poisson, and negative binomial methods. Death was incorporated into analyses by treating it as an additional event. The win ratio method and a method that jointly models hospitalizations and mortality were also considered. Using repeat events gave larger treatment benefts than time to frst event analysis. The negative binomial method for the composite of recurrent heart failure hospitalizations and cardiovascular death gave a rate ratio of 0.75 [95% confdence interval (CI) 0.62-0.91, P = 0.003], whereas the hazard ratio for time to frst heart failure hospitalization or cardiovascular death was 0.86 (95% CI 0.74-1.00, P = 0.050). Conclusions: In patients with preserved EF, candesartan reduces the rate of admissions for worsening heart failure, to a greater extent than apparent from analysing only frst hospitalizations. Recurrent events should be routinely incorporated into the analysis of future clinical trials in heart failure. © 2013 The Authors European Journal of Heart Failure.

References Powered by Scopus

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

2739Citations
N/AReaders
Get full text

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial

2665Citations
N/AReaders
Get full text

The robust inference for the cox proportional hazards model

2144Citations
N/AReaders
Get full text

Cited by Powered by Scopus

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

7973Citations
N/AReaders
Get full text

Efficacy and safety of low-dose colchicine after myocardial infarction

2024Citations
N/AReaders
Get full text

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC

1355Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Ostergren, J., … Yusuf, S. (2014). Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-preserved. European Journal of Heart Failure, 16(1), 33–40. https://doi.org/10.1002/ejhf.29

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 47

52%

Researcher 35

38%

Professor / Associate Prof. 6

7%

Lecturer / Post doc 3

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 64

73%

Mathematics 16

18%

Computer Science 5

6%

Chemistry 3

3%

Save time finding and organizing research with Mendeley

Sign up for free